Chloroxoquinoline
Chloroxoquinoline is an anticancer agent. Chloroxoquinoline damages the DNA templates of cancer cells, inducing DNA breaks and cell death, and inhibits cell invasion via down-regulating Rho/Rho kinase signaling pathway. Chloroxoquinoline enhances the radiation sensitivity of Lewis lung cancer cells and xenograft tumors in tumor-bearing mouse models but decreases efficacy after long term exposure in rat models by auto-induction effects on CYP1A and CYP3A. Chloroxoquinoline has a broad-spectrum anticancer activity, such as non-small-cell lung carcinoma (NSCLC), breast cancer and gastric cancer.
For research use only. We do not sell to patients.
- CAS No.: 23833-97-8
- Formula: C9H6ClNO
- Molecular Weight:179.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BGC-823 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
| BGC-823 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| BGC-823 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human BGC823 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human BGC823 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| DLD-1 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
| HCT-116 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
| HCT-116 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| HCT-8 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| HCT-8 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HCT8 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HCT8 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| HeLa | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| HeLa | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| HEp-2 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| HEp-2 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| HepG2 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
| HepG2 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| HepG2 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| MCF7 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| MCF7 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| NCI-H1650 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human NCI-H1650 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H1650 cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
| PC-3 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 28757067] |
| PC-3 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| RKO | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human RKO cells after 48 hrs by MTT assay
Cytotoxicity against human RKO cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
| RKO | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28942112] |
| SK-OV-3 | IC50 |
>10 μM
Compound: 11
|
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
|
[PMID: 30496987] |
Chemical Information
-
CAS No. 23833-97-8
-
Molecular Weight 179.60
-
Formula C9H6ClNO
-
SMILES
O=C1C=CNC2=C1C=CC(Cl)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Li X, et al. Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A. PLoS One. 2015 Sep 23;10(9):e0138875. [Content Brief]
[2]. Liu J, et al. [Chloroxoquinoline inhibits invasion in breast cancer via down-regulating Rho/Rho kinase signaling pathway]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019 Dec 25;48(6):631-637. Chinese. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz